PZI
- 产品代码
- PZI
- 器械名称
- Prescription Use Blood Glucose Meter For Near-Patient Testing
- 管理类别
- 第 2 类(Class II)
- 21 CFR 条款
- 21 CFR 862.1345
- FDA 专业组
- Clinical Chemistry
- 上市路径
- 需提交 510(k) 上市前通告
- 该代码近三年的 510(k)
- 14 件
FDA 分类定义
Intended for use in near-patient testing settings for in vitro diagnostic, multiple-patient use for the quantitative determination of glucose throughout all hospital and all professional healthcare settings for use in determining dysglycemia.
该代码近三年的 510(k)(4 件)
| 510(k) 号 | 批准日期 | 申请人 | 器械名称 | 摘要 |
|---|---|---|---|---|
| K252323 | 2026-06-12 | Roche Diagnostics | cobas pulse blood glucose monitoring system | |
| K221349 | 2024-11-19 | Taidoc Technology Corporation | XPER Technology PREMIUM Pro Blood Glucose Monitoring | |
| K220272 | 2024-04-26 | Roche Diagnostics | cobas pulse blood glucose monitoring system | FDA |
| K232075 | 2024-02-23 | Nova Biomedical Corporation | StatStrip Glucose Hospital Meter System |
FDA 官方分类页: PZI
分类与上市路径以 FDA 现行公告为准。本页数据来自 openFDA(CC0 公有领域),不构成注册策略建议。